https://www.selleckchem.com/products/fdi-6.html
001) compared with pretherapeutic levels in NSCLC and GC patients with lymph node or distant metastasis. Compared with pretherapeutic levels, IL-5 and IFN- levels largely increased as the tumor progresses ( 0.01). Higher IL-5 and IFN- levels before treatment indicated shorter progression-free survival in patients with NSCLC metastasis ( = 0.007, = 0.0111). Moreover, their levels also accurately reflected the pseudoprogression of two NSCLC patients to anti-PD-1 treatment. Our results suggested that serum IL-5 and IFN- levels could be
Like
Comment
Share
